NovaBay Pharmaceuticals (NBY) Stock Forecast, Price & News

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions

Is NovaBay Pharmaceuticals a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NovaBay Pharmaceuticals stock.
View analyst ratings for NovaBay Pharmaceuticals or view top-rated stocks.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) posted its quarterly earnings data on Tuesday, March, 29th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter. The biopharmaceutical company had revenue of $2.64 million for the quarter. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 67.65% and a negative net margin of 96.77%.
View NovaBay Pharmaceuticals' earnings history.

When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?

NovaBay Pharmaceuticals's stock reverse split on Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.

What price target have analysts set for NBY?

1 equities research analysts have issued 1 year price targets for NovaBay Pharmaceuticals' shares. Their forecasts range from $2.20 to $2.20. On average, they expect NovaBay Pharmaceuticals' stock price to reach $2.20 in the next year. This suggests a possible upside of 1,033.4% from the stock's current price.
View analysts' price targets for NovaBay Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are NovaBay Pharmaceuticals' key executives?

NovaBay Pharmaceuticals' management team includes the following people:

• Mr. Justin M. Hall Esq., Pres, CEO, Gen. Counsel, Chief Compliance Officer, Corp. Sec. & Director (Age 44, Pay $400.52k)
• Mr. Andrew D. Jones, CFO & Treasurer (Age 51, Pay $367.02k)
• Dr. Audrey Kunin M.D., Chief Product Officer & Director (Age 63, Pay $202.82k)
• Dr. Jeffrey Kunin M.D., Pres of DERMAdoctor (Age 59)

Who are some of NovaBay Pharmaceuticals' key competitors?

Some companies that are related to NovaBay Pharmaceuticals include Acasti Pharma (ACST), Cocrystal Pharma (COCP), IntelGenx Technologies (IGXT), Angion Biomedica (ANGN), Forward Pharma A/S (FWP), vTv Therapeutics (VTVT), Terns Pharmaceuticals (TERN), Elite Pharmaceuticals (ELTP), Bioxytran (BIXT), Aptorum Group (APM), Eledon Pharmaceuticals (ELDN), Synthetic Biologics (SYN), Galecto (GLTO), FSD Pharma (HUGE) and Moleculin Biotech (MBRX).
View all of NBY's competitors.

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Bionano Genomics (BNGO), Heat Biologics (HTBX), iBio (IBIO), Matinas BioPharma (MTNB), Novan (NOVN), ADMA Biologics (ADMA) and Vaxart (VXRT).

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."

Who are NovaBay Pharmaceuticals' major shareholders?

NovaBay Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.39%). Company insiders that own NovaBay Pharmaceuticals stock include Andrew D Jones, Audrey Kunin, Jeffrey Kunin, Jian Ping Fu, Justin Hall and Mijia Wu.
View institutional ownership trends for NovaBay Pharmaceuticals.

Which major investors are buying NovaBay Pharmaceuticals stock?

NBY stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought NovaBay Pharmaceuticals stock in the last two years include Andrew D Jones, Audrey Kunin, Jeffrey Kunin, and Justin Hall.
View insider buying and selling activity for NovaBay Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovaBay Pharmaceuticals' stock price today?

One share of NBY stock can currently be purchased for approximately $0.19.

How much money does NovaBay Pharmaceuticals make?

NovaBay Pharmaceuticals has a market capitalization of $9.98 million and generates $9.93 million in revenue each year. The biopharmaceutical company earns $-11.03 million in net income (profit) each year or ($0.17) on an earnings per share basis.

How many employees does NovaBay Pharmaceuticals have?

NovaBay Pharmaceuticals employs 22 workers across the globe.

What is NovaBay Pharmaceuticals' official website?

The official website for NovaBay Pharmaceuticals is novabay.com.

How can I contact NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at (510) 899-8800, via email at [email protected], or via fax at 510-474-1577.